DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactOrders & Deals

Indoco Remedies Limited — Acquisition

NSE 1 hr ago·28 Sept 2026, 3:50 pm

Indoco Remedies

Indoco Remedies Limited has incorporated a wholly-owned subsidiary named Warren Lifesciences Private Limited. This new entity is a separate legal structure created by the parent company to manage specific business operations.

This move is a strategic step for Indoco to expand its business footprint. It allows the company to focus on new ventures or specific product lines under a distinct corporate umbrella, potentially improving operational efficiency and strategic focus.

Investors should monitor the specific business objectives of this new subsidiary. Its success will depend on how effectively it integrates into Indoco's existing operations and contributes to the overall growth of the parent company.